Companies · Healthtech

4C Medical Technologies, Inc.

Maple Grove · Healthtech · refined from filed group “Other Technology

Diligence memoA one-page analyst read on 4C Medical Technologies, Inc. — recommendation, valuation, rhythm, risks.
$145.5M
Total raised · real
6
Rounds
1.0×
Latest step-up
Top 4%
Sector rank · raised
Series C
Latest stage · inferred · Wed Mar 04 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

4C Medical Technologies, Inc. looks fair against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the healthtech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.16× the median modeled value of Series C Healthtech companies in 2025–2027 (19 peers) — value vs value, same stage and era.
  • Within the normal band (116% of peer median) for its niche.
Active
  • Last raise 4 mo ago; this sector typically re-raises about every 14 months.
  • Raising on or ahead of the sector's normal rhythm.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Healthtech

4C Medical Technologies, Inc. is one of 2138 Healthtech companies tracked from Maple Grove. By capital raised it ranks among the largest (ahead of 97% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
80
Investors (latest)
2026-03-04
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250M$500M$750M$1.0BSeed · 2018-04-30 Raised $3.1M (real) Modeled valuation $85M (est)Seed2018Series B · 2018-09-04 Raised $17M (real) Modeled valuation $430M (est)Series B2018Series B · 2019-09-25 Raised $8.2M (real) Modeled valuation $203M (est)Series B2019Series B · 2020-05-22 Raised $10M (real) Modeled valuation $248M (est)Series B2020Pre-Seed · 2020-05-22 Raised $100K (real) Modeled valuation $3.4M (est)Pre-Seed2020Series B · 2021-11-04 Raised $35M (real) Modeled valuation $565M (est)Series B2021Series C · 2025-03-04 Raised $72M (real) Modeled valuation $504M (est)Series C2025Series C · 2026-03-04 Raised $72M (real) Modeled valuation $383M (est)Series C2026+$17M+$8.2M+$10M+$100K+$35M+$72M+$72MCumulative $217M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$3.1M · 2018
Series B$17.3M · 2018no Series A on file
Series B extension$8.2M · 2019
Series B extension$10.0M · 2020
Bridge · Series B-stage$100K · 2020smaller follow-on
Series B extension$35.3M · 2021
Series C$71.6M · 2025
Series C extension$71.6M · 2026

Stages are modeled from round size (public records carry no series label). No record for: Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 80%.

Modeled valuation trajectory
$382.9M
Base estimate est.
$260.3M
Conservative case
$462.1M
Upside case
$477.4M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the healthtech sector profile. Directional, not a quoted figure.

Seed · modeled $85.2M · 2018-04-302018Series B · modeled $429.9M · 2018-09-04Series B · modeled $202.9M · 2019-09-25Series B · modeled $247.8M · 2020-05-22Pre-Seed · modeled $3.4M · 2020-05-22Series B · modeled $565.1M · 2021-11-04Series C · modeled $504.5M · 2025-03-04Series C · modeled $382.9M · 2026-03-042026
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
73%
Survival probability
55% low · 85% high
1.32×/yr
Annual markup
1.51×/yr upside case
0.3 yr
Elapsed time used
0.3 yr actual, capped for stale marks
healthtech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
13 mo
Avg between rounds
$18.5M/yr
Capital velocity
8.2 yr
On record since
2018
First round
8
Rounds on file
How it compares to the market

Benchmarked against 2138 companies in Healthtech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 33× above median
This company$145.5M
Sector median$4.5M
Latest round — vs other Series C rounds in sector (real $, this stage) 1.5× above median
This company$71.6M
Sector median$46.5M
Modeled value — vs sector median (estimate, all stages) 11× above median
This company$382.9M
Sector median$33.8M

Raised more than 97% of sector peers (real $). Modeled value above 91% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #6 of 19.

This companyCohort peer
$100.0M$1.0B$10.0M$100.0M$1.0BCapital raised (log)Thyme Care, Inc. · Series C Raised $214.3M · modeled $667.8M (est)Cohere Health Inc. · Series C Raised $166.1M · modeled $604.1M (est)All Inspire Health, Inc. · Series C Raised $137.4M · modeled $549.8M (est)Harbor Health Team Inc. · Series C Raised $189.1M · modeled $516.2M (est)Apreo Health, Inc. · Series C Raised $81.8M · modeled $512.9M (est)Sprinter Health, Inc. · Series C Raised $55.0M · modeled $378.5M (est)Diana Health, Inc. · Series C Raised $66.0M · modeled $344.9M (est)Equip Health, Inc. · Series C Raised $163.8M · modeled $343.2M (est)Ascend Wellness Holdings, Inc. · Series C Raised $219.1M · modeled $330.6M (est)XO Health Inc. · Series C Raised $52.2M · modeled $323.4M (est)Health Catalyst, Inc. · Series C Raised $414.2M · modeled $323.3M (est)4C Medical Technologies, Inc. (this company) Raised $145.5M · modeled $382.9M (est)4C Medical Technologies, Inc.
CompanyStageRaised · realValue · estvs peer med.
Thyme Care, Inc.Series C$214.3M$667.8M2.02×
Cohere Health Inc.Series C$166.1M$604.1M1.83×
All Inspire Health, Inc.Series C$137.4M$549.8M1.66×
Harbor Health Team Inc.Series C$189.1M$516.2M1.56×
Apreo Health, Inc.Series C$81.8M$512.9M1.55×
4C Medical Technologies, Inc. this companySeries C$145.5M$382.9M1.16×
Sprinter Health, Inc.Series C$55.0M$378.5M1.14×
Diana Health, Inc.Series C$66.0M$344.9M1.04×
Equip Health, Inc.Series C$163.8M$343.2M1.04×
Ascend Wellness Holdings, Inc.Series C$219.1M$330.6M1.00×
XO Health Inc.Series C$52.2M$323.4M0.98×
Health Catalyst, Inc.Series C$414.2M$323.3M0.98×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$3.1M2018-04-30$15.4M$85.2M90%
Series B$17.3M2018-09-04$96.4M$429.9M90%
Series B$8.2M2019-09-25$45.5M$202.9M90%
Series B$10.0M2020-05-22$55.6M$247.8M90%
Pre-Seed$100K2020-05-22$556K$3.4M90%
Series B$35.3M2021-11-04$195.8M$565.1M90%
Series C$71.6M2025-03-04$477.4M$504.5M90%
Series C$71.6M2026-03-04$477.4M$382.9M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$3.1M2018-04-30
    • First recorded raise — entered as Seed.
    • 29 investors on this round.
  2. Series B$17.3M2018-09-04
    • Came back fast: 4 mo vs the ~14 mo sector norm.
    • Round 5.6× larger than the prior — scaling up.
    • 23 investors on this round.
  3. Series B$8.2M2019-09-25
    • Raised 13 mo later, in step with the ~14 mo sector norm.
    • Round 2.1× smaller than the prior — bridge or down round.
    • 45 investors on this round.
  4. Series B$10.0M2020-05-22
    • Came back fast: 8 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 39 investors on this round.
  5. Pre-Seed$100K2020-05-22
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 100.0× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  6. Series B$35.3M2021-11-04
    • Raised 17 mo later, in step with the ~14 mo sector norm.
    • Round 352.5× larger than the prior — scaling up.
    • 53 investors on this round.
  7. Series C$71.6M2025-03-04
    • Raised again after 40 mo — slower than the ~14 mo sector norm.
    • Round 2.0× larger than the prior — scaling up.
    • 80 investors on this round.
  8. Series C$71.6M2026-03-04
    • Raised 12 mo later, in step with the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 80 investors on this round.
Intelligence
2027 ~Q2
Modeled next raise · ~13mo cadence
$71.6M
Modeled next size est.range $71.6M$114.6M
1.0×
Last step-up
$18.5M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Buzz Benson7 other2025-03
Jonathan Chen2 other2025-03
James E. Flaherty1 other2018-04
Jeffrey Chambers1 other2025-03
Rhonda Robb1 other2025-03
Robert J. Thatcher1 other2018-04
Buzz J. Benson2019-09
Buzz W. Benson2020-05
Harley Handegard2025-03
Jeffrey W. Chambers2018-04
Jonathan J. Chen2018-09
Jonathan W. Chen2020-05
Katherine J. Kumar2018-04
Katherine Kumar2025-03
Katherine W. Kumar2020-05
Rhonda W. Robb2021-11
Saravana J. Kumar2018-04
Saravana Kumar2020-05
Scott W. Youngstrom2020-05
William J. Hoffman2018-04
Registry & provenance

4C Medical Technologies, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1692028
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Aerin Medical Inc.HealthtechSeries C$145.2M$243.2Msame sector · same stage
Conformal Medical, Inc.HealthtechSeries C$145.1M$200.3Msame sector · same stage
ShockWave Medical, Inc.HealthtechSeries C$144.8M$255.8Msame sector · same stage
Grow Care, Inc.HealthtechSeries C$149.3M$485.7Msame sector · same stage
Eleanor Health Holdings, LlcHealthtechSeries C$138.0M$210.1Msame sector · same stage
All Inspire Health, Inc.HealthtechSeries C$137.4M$549.8Msame sector · same stage
CSA Medical, Inc.HealthtechSeries C$156.7M$483.7Msame sector · same stage
Route 92 Medical, Inc.HealthtechSeries C$158.1M$428.5Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
4C Health Solutions, Inc.HealthtechSeed$1.9M97%
FourC Health, Inc.HealthtechPre-Seed$7.6M91%
4G Clinical, LLCHealthtechSeries A$330.0M89%
Digital Medical Tech, Inc.HealthtechSeed$82.0M86%
4D Healthware LlcHealthtechSeed$58.4M86%
RX4 Health Inc.HealthtechPre-Seed$2.2M86%
Real Time Medical Systems, LLCHealthtechSeries B$367.5M84%
HealthArc Worldwide Inc.HealthtechSeries A$32.1M84%
Frequently asked
How much funding has 4C Medical Technologies, Inc. raised?
4C Medical Technologies, Inc. has raised approximately $145.5M in disclosed capital across 6 recorded financing rounds, aggregated from public filings.
What is 4C Medical Technologies, Inc.'s estimated valuation?
Provath's modeled valuation for 4C Medical Technologies, Inc. is approximately $382.9M (modeled range $260.3M–$462.1M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is 4C Medical Technologies, Inc. at?
4C Medical Technologies, Inc.'s latest modeled financing stage is Series C. Its most recent recorded round closed around Wed Mar 04.
What does 4C Medical Technologies, Inc. do and where is it based?
4C Medical Technologies, Inc. operates in the Healthtech sector, based in Maple Grove.
Explore related

See where 4C Medical Technologies, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at 4C Medical Technologies, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.